PCSA (Processa Pharmaceuticals) Ending Cash Position: $1.69 Mil (As of Mar. 2026)


PCSA Processa Pharmaceuticals Inc PCSA
28 GF Score
Price $2.16
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals Ending Cash Position?

Processa Pharmaceuticals PCSA +9.64% 28 Ending Cash Position is $1.69 Mil as of Mar. 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Processa Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 was $1.69 Mil.

Processa Pharmaceuticals's quarterly Ending Cash Position declined from Sep. 2025 ($6.31 Mil) to Dec. 2025 ($5.54 Mil) and declined from Dec. 2025 ($5.54 Mil) to Mar. 2026 ($1.69 Mil).

Processa Pharmaceuticals's annual Ending Cash Position declined from Dec. 2023 ($4.71 Mil) to Dec. 2024 ($1.19 Mil) but then increased from Dec. 2024 ($1.19 Mil) to Dec. 2025 ($5.54 Mil).

Processa Pharmaceuticals Ending Cash Position Related Terms

Processa Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Ending Cash Position Chart

Processa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.50 6.50 4.71 1.19 5.54

Processa Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.90 6.94 6.31 5.54 1.69
PCSA
28GF Score
Processa Pharmaceuticals Inc PCSA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Processa Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.191+4.346
=5.54

Processa Pharmaceuticals's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.537+-3.846
=1.69

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.69 Mil mean?
Processa Pharmaceuticals (PCSA) has a Ending Cash Position of $1.69 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Processa Pharmaceuticals and its competitors.
Is Processa Pharmaceuticals' Ending Cash Position too high?
Processa Pharmaceuticals' current Ending Cash Position is $1.69 Mil. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' Ending Cash Position compare to ELAB and MBIO?
Processa Pharmaceuticals' Ending Cash Position of $1.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current Ending Cash Position is $1.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current Ending Cash Position of $1.69 Mil. The current Ending Cash Position is $1.69 Mil. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Ending Cash Position is $1.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score

Get the complete analysis for PCSA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price